Amyloidosis Drug PROs Supported Clinical Meaningfulness Of Objective Measures
Executive Summary
In pivotal trials for Alnylam’s Onpattro and Ionis’ Tegsedi, statistically persuasive results on a patient-reported, quality-of-life measure were needed to show the drugs had a meaningful benefit on how hATTR patients with polyneuropathy feel and function, US FDA said.
You may also be interested in...
Tegsedi Clinical Development Timeline
Chronicle of the development and US FDA review of Ionis Pharmaceuticals’ inotersen for treatment of polyneuropathy of hATTR amyloidosis.
Onpattro Clinical Development Timeline
Chronicle of the development and US FDA review of Alnylam’s patisiran for polyneuropathy of hATTR amyloidosis.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.